Red Dragon: Low-cost Access to the Surface of Mars using Commercial Capabilities

We will discuss the feasibility of using a minimally-modified variant of a SpaceX Dragon capsule as a low-cost, large-capacity, near-term, Mars lander for scientific and human-precursor missions. We have been evaluating such a Red Dragon platform as an option for a Discovery Program mission concept. A Red Dragon lander has the potential to be low cost primarily because it would be derived from a routinely-flying spacecraft. Dragon is being developed to ferry cargo and crew to and from the International Space Station (ISS). The cargo variant is currently undergoing test flights, which will be followed by standard ISS cargo missions and, eventually, crewed flights. The human variant, unlike other Earth-return vehicles, appears to also have most of the capabilities necessary to land on Mars. In particular, it has a set of high-thrust, throttleable, storable bi-propellant Super- Draco engines integrated directly into the capsule which are intended for launch abort and powered landings on Earth. These thrusters suggest the possibility of a parachute-free, fully-propulsive deceleration at Mars from supersonic speeds to the surface. Concepts for large, human-relevant landers (see, e.g., [1]) also often employ supersonic retro-propulsion; Red Dragon's entry, descent, and landing approach would scale to those landers. Further, SpaceX's Falcon Heavy launch vehicle, currently under development and expected to have its first flight in 2013, will be capable of sending Dragon on a trajectory to Mars. We will discuss our motivation for exploring a Red Dragon lander, the primary technical questions which determine its feasibility, and the current results of our analysis. In particular, we will examine entry, descent, and landing (EDL) in detail. We will describe the modifications to Dragon necessary for interplanetary cruise, EDL, and operations on the Martian surface

Safety and Feasibility of Long-term Intravenous Sodium Nitrite Infusion in Healthy Volunteers

BACKGROUND: Infusion of sodium nitrite could provide sustained therapeutic concentrations of nitric oxide (NO) for the treatment of a variety of vascular disorders. The study was developed to determine the safety and feasibility of prolonged sodium nitrite infusion. METHODOLOGY: Healthy volunteers, aged 21 to 60 years old, were candidates for the study performed at the National Institutes of Health (NIH; protocol 05-N-0075) between July 2007 and August 2008. All subjects provided written consent to participate. Twelve subjects (5 males, 7 females; mean age, 38.8±9.2 years (range, 21-56 years)) were intravenously infused with increasing doses of sodium nitrite for 48 hours (starting dose at 4.2 µg/kg/hr; maximal dose of 533.8 µg/kg/hr). Clinical, physiologic and laboratory data before, during and after infusion were analyzed. FINDINGS: The maximal tolerated dose for intravenous infusion of sodium nitrite was 267 µg/kg/hr. Dose limiting toxicity occurred at 446 µg/kg/hr. Toxicity included a transient asymptomatic decrease of mean arterial blood pressure (more than 15 mmHg) and/or an asymptomatic increase of methemoglobin level above 5%. Nitrite, nitrate, S-nitrosothiols concentrations in plasma and whole blood increased in all subjects and returned to preinfusion baseline values within 12 hours after cessation of the infusion. The mean half-life of nitrite estimated at maximal tolerated dose was 45.3 minutes for plasma and 51.4 minutes for whole blood. CONCLUSION: Sodium nitrite can be safely infused intravenously at defined concentrations for prolonged intervals. These results should be valuable for developing studies to investigate new NO treatment paradigms for a variety of clinical disorders, including cerebral vasospasm after subarachnoid hemorrhage, and ischemia of the heart, liver, kidney and brain, as well as organ transplants, blood-brain barrier modulation and pulmonary hypertension. CLINICAL TRIAL REGISTRATION INFORMATION: http://www.clinicaltrials.gov; NCT00103025